Myeloma Facts

Why Early Detection of MM Is Crucial

As incidence continues to increase, early detection may help provide patients more treatment options.¹ Despite currently available treatments, multiple myeloma remains incurable, and most patients will relapse and become refractory to these treatments.² In some patients, the cancer may respond to initial treatment, but not to treatment following a relapse.²

New agents are necessary so that patients and physicians can have options as the disease progresses and patients relapse and become refractory to treatments.

Recent research in MM Importance of MRD-Patient factors & impacts

Multiple Myeloma Shows No Signs of Slowing Down

In 2012, multiple myeloma incidence in the United States stood at ~21,000 new cases; by 2025, that number is projected to grow to ~37,000^3,4

Comparably, from 2015 to 2030 in the EU, new cases of multiple myeloma are expected to increase from ~35,000 to over ~43,000 new cases⁵

Each year, there are more than 130,000 new diagnoses of multiple myeloma worldwide⁶
This disease is most frequently diagnosed in people aged 65-75 years⁷
Relapsed and refractory multiple myeloma (RRMM) is a complicated and heterogeneous disease, as it is continuously developing resistance to treatments⁸

Almost all people with multiple myeloma will still relapse on or after treatments. Once these patients relapse, they become more difficult to treat.² There is a need for new agents so that patients and physicians can have options as the disease progresses.

REFERENCES: 1. American Cancer Society. Can multiple myeloma be found early? https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/detection.html. Updated February 2018. Accessed March 2021. 2. Multiple Myeloma Research Foundation. Multiple myeloma prognosis. https://themmrf.org/multiple-myeloma/prognosis. Accessed September 5, 2019. 3. João C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, Silva MG. Long-term survival in multiple myeloma. Clinical Case Reports. 2014;2(5):173-179. doi:10.1002/ccr3.76. 4. Kanas G, Clark O, Keeven K, Nersesyan K, Sansbury L, Hogea C. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA. Poster presented at: The 62nd American Society of Hematology Annual Meeting and Exposition; December 5–8, 2020; Virtual Format. 5. Schey SA, Morris J, Maguire Á, Dhanasiri S. Quantifying the burden of multiple myeloma across Europe. Blood. 2016;128(22):5960. 6. International Myeloma Foundation. March Myeloma Action Month website. https://mam.myeloma.org/learn-more-about-multiple-myeloma/. Accessed March 2021. 7. National Cancer Institute. Cancer stat facts: myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed January 2019. 8. Larsen J, Kumar S. Evolving paradigms in the management of multiple myeloma: novel agents and targeted therapies. Rare Cancers Ther. 2015;3:47–68. doi:10.1007/s40487-015-0009-4